Results 21 to 30 of about 106,875 (237)
GSK-3 inhibitors for Alzheimer’s disease
Expert Review of Neurotherapeutics, 2007 Glycogen synthase kinase (GSK)-3 has been proposed as the link between the two histopathological hallmarks of Alzheimer's disease, the extracellular senile plaques made of beta-amyloid and the intracellular neurofibrillary tangles made of hyperphosphorylated tau.
Ávila, Jesús, Hernández, Félix
openaire +3 more sources
GSK-3 and mitochondria in cancer cells [PDF]
Frontiers in Oncology, 2013 GSK-3 is a multifunctional kinase that is located in the cytosol, nucleus, and mitochondria of all cell types, and it is involved in the pathogenesis of a variety of diseases. In cancer, GSK-3 modulates the response of the cell death machinery to stress stimuli, including chemotherapeutics.
CHIARA, FEDERICA, RASOLA, ANDREA
openaire +4 more sources
Frontiers in Endocrinology, 2014 Glycogen synthase kinase-3 (Gsk-3) activity is an important regulator of numerous signal transduction pathways. Gsk-3 activity is the sum of two largely redundant proteins, Gsk-3α and Gsk-3β, and in general, Gsk-3 is a negative regulator of cellular ...
Colleen M Bartman +6 more
doaj +1 more source
Lack of effect of mood stabilizers or neuroleptics on GSK-3 protein levels and GSK-3 activity [PDF]
The International Journal of Neuropsychopharmacology, 2003 Glycogen synthase kinase (GSK)-3 protein levels and GSK-3 activity were previously found to be over 40% reduced in the post-mortem prefrontal cortex of schizophrenic patients. Lithium and valproate have been reported to selectively inhibit GSK-3. We hypothesized that in-vivo administration of lithium and valproate would result in up-regulation of GSK-3
Nitsan, Kozlovsky +3 more
openaire +2 more sources
GSK-3: a multifaceted player in acute leukemias
Leukemia, 2021 Glycogen synthase kinase 3 (GSK-3) consists of two isoforms (α and β) that were originally linked to glucose metabolism regulation. However, GSK-3 is also involved in several signaling pathways controlling many different key functions in healthy cells.
A. M. Martelli +4 more
openaire +5 more sources
N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation.
The Journal of biological chemistry, 2007 Peer ...
Goñi-Oliver, Paloma +3 more
openaire +3 more sources
Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
BMC Cancer, 2010 Background Glycogen Synthase Kinase-3 (GSK-3) α and β are two serine-threonine kinases controlling insulin, Wnt/β-catenin, NF-κB signaling and other cancer-associated transduction pathways.
Colpo Anna +12 more
doaj +1 more source
The role of GSK‐3 in synaptic plasticity [PDF]
British Journal of Pharmacology, 2008 Glycogen synthase kinase‐3 (GSK‐3), an important component of the glycogen metabolism pathway, is highly expressed in the CNS. It has been implicated in major neurological disorders including Alzheimer's disease, schizophrenia and bipolar disorders. Despite its central role in these conditions it was not known until recently whether GSK‐3 has neuronal ...
Peineau, Stéphane +6 more
openaire +4 more sources
GSK-3: functional insights from cell biology and animal models
Frontiers in Molecular Neuroscience, 2011 Glycogen synthase kinase-3 (GSK-3) is a widely expressed and highly conserved serine/threonine protein kinase encoded in mammals by two genes that generate two related proteins: GSK-3α and GSK-3β.
Oksana eKaidanovich-Beilin +1 more
doaj +1 more source
Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent. [PDF]
PLoS ONE, 2013 Glycogen synthase kinase-3 (GSK-3) inhibitors have been postulated as useful therapeutic tools for the treatment of chronic neurodegenerative and neuropsychiatric diseases.
Raquel Gómez-Sintes, José J Lucas
doaj +1 more source